Created with Sketch.
18 minutes | a day ago
Biotech trends in COVID era: the pharmaphorum podcast
In episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently took up the position of CEO at the Paris-based biopharmaceutical company Pharnext.
13 minutes | a month ago
GSK and eosinophil research: the pharmaphorum podcast
GlaxoSmithKline’s Nucala (mepolizumab) last month became the first and only biologic treatment approved in the US for Hypereosinophilic Syndrome (HES).It’s part of the company’s focus on eosinophil-driven diseases and ahead of that regulatory milestone I spoke with Tiffany Robinson-Smith, who’s global medical affairs lead for biologics at GSK, about eosinophils and why they’re an important element of her company’s research programmes.
16 minutes | 2 months ago
Gitte Aabo on telemedicine and her time at LEO Pharma: the pharmaphorum podcast
In this episode of the podcast Gitte discusses telemedicine, GN Hearing’s work in this area – and the impact of COVID-19, plus her time at LEO Pharma.
23 minutes | 3 months ago
The Alderley Park Discovery Podcast: COVID testing and the Lighthouse Lab
The Alderley Park Discovery Podcast, produced in partnership with pharmaphorum, presents perspectives on UK and global bioscience innovation trends, with input from key experts including managing director and leader of Bruntwood SciTech’s Alderley Park Dr Kath Mackay.
19 minutes | 3 months ago
Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast
Anlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing and how it could offer a route to target the current coronavirus pandemic.
20 minutes | 4 months ago
Novartis, company culture and COVID-19: the pharmaphorum podcast
Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face
22 minutes | 5 months ago
Amgen and science education: the pharmaphorum podcast
Harvard University launched LabXchange in January and the free science education platform has acquired new resonance during the
21 minutes | 6 months ago
UK pharma leadership and COVID-19: the pharmaphorum podcast
The COVID-19 pandemic has forced significant changes on the pharmaceutical industry as companies scramble to protect employees, ensure
14 minutes | 8 months ago
Eisai and Alexa skills in epilepsy: the pharmaphorum podcast
Voice technology like Amazon’s Alexa is taking some big steps forward in healthcare and in the pharmaceutical world
21 minutes | 9 months ago
Digital health and interoperability: the pharmaphorum podcast
One of the biggest barriers to applying precision medicine to clinical trials and patient engagement is getting different
32 minutes | a year ago
Roche, big data and patient outcomes: the pharmaphorum podcast
In the first pharmaphorum podcast of 2020 Roche’s Conor Megaw talks about his company’s approach to big data
29 minutes | a year ago
Pfizer and the UK cancer landscape: the pharmaphorum podcast
Pfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK
43 minutes | a year ago
Life sciences leadership: the pharmaphorum podcast
Episode 15 of the pharmaphorum podcast marked a return visit for leading life sciences industry authority Professor Brian
22 minutes | a year ago
AstraZeneca and lung cancer: the pharmaphorum podcast
This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, Global Franchise Head, Tagrisso TDR
26 minutes | a year ago
Lung cancer’s patient information gap: the pharmaphorum podcast
For episode 13 of the pharmaphorum podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s
59 minutes | a year ago
Addressing global health challenges: the pharmaphorum podcast
For episode 11 of the pharmaphorum podcast our CEO and founder Dr Paul Tunnah took the helm to record a special roundtable episode in Philadelphia with the International AIDS Vaccine Initiative (IAVI).
20 minutes | 2 years ago
Gene therapy and market access: the pharmaphorum podcast
For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK.The Cambridge, Massachusetts-based company has gone from being a gene therapy start-up to having three potential blockbusters on its books, with a CAR-T cancer medicine and potential treatments for a type of sickle-cell disease and a rare and deadly genetic brain disease.
24 minutes | 2 years ago
AMR research and Matoke Pharma: the pharmaphorum podcast
Re-engineered honey has proved to be a novel and successful development for Matoke Pharma, as well as a crucial step on the UK biotech company’s plans to target antimicrobial resistance (AMR).In episode 9 of the pharmaphorum podcast Alan Westwood explains the research behind Matoke’s SurgihoneyRO, an antimicrobial wound gel that has a CE mark in Europe, and how the company is taking that product’s reactive oxygen (RO) component to develop novel pharmaceutical antimicrobials.
29 minutes | 2 years ago
GSK and digital disruption: the pharmaphorum podcast
Digital innovation and disruption in healthcare are the subject of this episode of the pharmaphorum podcast, for which I visited GlaxoSmithKline at their Stockley Park base to speak with Kai Gait, a senior global digital strategy director at the company.
12 minutes | 2 years ago
Ipsen on neurotoxin research: the pharmaphorum podcast
For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.
Terms of Service
© Stitcher 2020